Treatment modalities
| . | 1980-1994 . | 1995-2004 . | P . |
|---|---|---|---|
| Treated, n (%) | 212 (48.3) | 189 (53.8) | NS |
| First-line treatment | < .001 | ||
| Alkylating agents, % | 96.4 | 48.3 | |
| PA, % | 3.6 | 22.8 | |
| PA + other cytotoxics, % | 18.9 | ||
| Rit + PA in combination, % | 10.0 | ||
| Hemopoietic stem cell transplantation, n (%) | 13 (2.9) | 34 (9.3) | < .001 |
| Autologous, n (%) | 8 (1.8) | 15 (4.1) | .045 |
| Allogeneic, n (%) | 5 (1.1) | 19 (5.2) | .001 |
| Conventional allogeneic, n (%) | 5 (1.1) | 13 (3.6) | .018 |
| RIC, n (%) | 0 | 6 (1.6) | .008 |
| Any time | < .001 | ||
| PA, %* | 16.0 | 11.0 | |
| PA + other cytotoxics, % | 11.0 | 42.0 | |
| Rit + PA in combination, % | 0.5 | 13.0 |
| . | 1980-1994 . | 1995-2004 . | P . |
|---|---|---|---|
| Treated, n (%) | 212 (48.3) | 189 (53.8) | NS |
| First-line treatment | < .001 | ||
| Alkylating agents, % | 96.4 | 48.3 | |
| PA, % | 3.6 | 22.8 | |
| PA + other cytotoxics, % | 18.9 | ||
| Rit + PA in combination, % | 10.0 | ||
| Hemopoietic stem cell transplantation, n (%) | 13 (2.9) | 34 (9.3) | < .001 |
| Autologous, n (%) | 8 (1.8) | 15 (4.1) | .045 |
| Allogeneic, n (%) | 5 (1.1) | 19 (5.2) | .001 |
| Conventional allogeneic, n (%) | 5 (1.1) | 13 (3.6) | .018 |
| RIC, n (%) | 0 | 6 (1.6) | .008 |
| Any time | < .001 | ||
| PA, %* | 16.0 | 11.0 | |
| PA + other cytotoxics, % | 11.0 | 42.0 | |
| Rit + PA in combination, % | 0.5 | 13.0 |
PA indicates purine analogs; Rit, rituximab; and RIC, reduced-intensity allogeneic.